Verantos Receives FDA Support to Demonstrate Advanced Approaches to RWE
Verantos announced that it has received a grant award from the U.S. Food and Drug Administration to implement a multi-year advanced real-world evidence (RWE) study.
The program, "Transforming Real-World Evidence with Unstructured and Structured Data to Advance Tailored Therapy" (TRUST), was sponsored by the FDA Center for Drug Evaluation and Research.
As RWE is increasingly used to make clinical assertions and refine the standard of care, rigorous approaches are required to meet evidentiary standards. This three-year study will apply advanced RWE to a clinical scenario, and data quality will be studied by comparing traditional approaches to advanced approaches. The study, FD-20-030, includes innovations in deep phenotyping, data linkage, and phenotype accuracy measurement.
For more information, click here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
